PTAB: Petitioner Not Obliged to Address Evidence of Object Indicia That is Neither Tethered to the Claim nor Previously Found Persuasive

Mar 5, 2021

Reading Time : 2 min

The petitioner challenged claims of a patent whose parent had been challenged previously in an IPR by a third party. In that earlier proceeding, the board found that all of the parent patent’s claims were unpatentable for obviousness, despite the patent owner’s attempt to show nonobviousness by submitting evidence of objective indicia.

In the IPR challenging the claims of the child patent, the patent owner argued in its preliminary response that the petitioner should have addressed objective indicia evidence that was present in the specification. The board’s institution decision “did not expressly address” that argument. Following institution, the patent owner sought rehearing, arguing in part that the board had erred by overlooking the objective indicia evidence, and that the petition was “facially deficient” because it did not address the evidence present in the specification and original prosecution history.

The board rejected the patent owner’s contention that the board had erred. First, the board explained that the child patent did “not have an extensive litigation record of objective indicia supporting nonobviousness” and so case law requiring a petitioner to address such evidence was inapposite. Rather, in the IPR proceeding challenging the parent patent, the board had found that patent owner’s objective indicia evidence did not establish nonobviousness. Second, the board explained that the objective indicia evidence concerned a limitation that was not present in the challenged claims. As such, for either of those reasons, the petitioner did not have to address the evidence in the petition. The board further explained that to the extent the patent owner had submitted additional evidence on this issue, the petitioner had not yet had an opportunity to respond, and so the record could be developed during trial.

The board completed its analysis by turning to the merits of the patent owner’s evidence at the institution stage. The board found that the patent owner had made only “generalized arguments” and had not presented “sufficient factual evidence” to establish its allegations of unexpected results in support of nonobviousness. In conclusion, the board denied the request for rehearing for failing to show the board had abused its discretion in instituting the IPR.

Practice Tip: Both sides in America Invents Act (AIA) proceedings should carefully consider whether evidence of objective indicia that is relevant to the challenged claims has been fully developed in prior proceedings, such as during prosecution, reexamination, an AIA trial, an International Trade Commission (ITC) investigation or a district court litigation. A petitioner may need to address objective evidence of nonobviousness or risk denial of institution if the patent owner successfully argues that the evidence ought to have been addressed in the petition. Conversely, in the absence of a fully developed record of objective indicia evidence, a petitioner may not be obliged to address that evidence, and a patent owner may be better served by attacking the petition in other ways.

Liquidia Techs., Inc. v. United Therapeutics Corp., IPR2020-00770, Paper 14 (PTAB Mar. 1, 2021)

Share This Insight

Previous Entries

IP Newsflash

March 24, 2025

The Federal Circuit affirmed a Patent Trial and Appeal Board (PTAB) final written decision holding that the prior art exception of AIA Section 102(b)(2)(B) does not apply to a prior sale by an inventor when the sale is conducted in private. According to the Federal Circuit, a sale must disclose the relevant aspects of the invention to the public to qualify for the prior art exception of Section 102(b)(2)(B).

...

Read More

IP Newsflash

March 21, 2025

Under the Lanham Act, a plaintiff who prevails on a trademark infringement claim may be entitled to recover the “defendant’s profits” as damages. The Supreme Court in Dewberry Group, Inc. v. Dewberry Engineers Inc. unanimously construed “defendant’s profits” in 35 USC § 1117(a) to mean that only the named defendant’s profits can be awarded, not the profits of other related corporate entities. The Court, however, left open the possibility that other language in § 1117(a) may allow for damages linked to the profits of related entities, if properly raised and supported.

...

Read More

IP Newsflash

March 13, 2025

In a series of rulings on a motion in limine, the District of Delaware recently distinguished between what qualifies as being incorporated by reference and what does not for the purposes of an anticipation defense. In short, a parenthetical citation was held to be insufficient, while three passages discussing a cited reference met the test.

...

Read More

IP Newsflash

March 4, 2025

On February 28, 2025, the USPTO announced that it was rescinding former Director Vidal’s 2022 memorandum on discretionary denials by the Patent Trial and Appeal Board. The 2022 memorandum effectively narrowed the application of discretionary denials in cases with parallel district court litigation by specifying instances where discretionary denial could not be issued. With the withdrawal of the memorandum, individual PTAB panels will regain flexibility in weighing discretionary denials. While the long-term effect of that increased flexibility is not yet known, the immediate effect is likely to be a shift towards the discretionary analysis applied by PTAB panels before the issuance of the memorandum.

...

Read More

IP Newsflash

March 3, 2025

A District of Delaware judge recently granted a defendant’s motion to include a patent prosecution bar in its proposed protective order after determining that litigation counsel’s ability to practice before the Patent Office—without ever having represented the plaintiffs at the Patent Office in the past—weighed heavily in favor of the bar.

...

Read More

IP Newsflash

February 12, 2025

The Federal Circuit recently reversed a district court decision that found a patent that did not describe after-arising technology failed to satisfy the written description requirement. In so doing, the Federal Circuit explained that written description and enablement are evaluated based on the subject matter that is claimed, not the products that practice those claims. As a result, the patentee was not required to describe unclaimed, later-discovered features of the accused products despite the broad language in the claims that undisputedly covered the products.

...

Read More

IP Newsflash

January 24, 2025

The District of Delaware recently rejected a patentee’s argument that non-production of an opinion letter from counsel, combined with knowledge of the patent, warranted a finding that defendant induced infringement.

...

Read More

IP Newsflash

January 17, 2025

The District of Delaware recently denied a motion to dismiss a patent infringement complaint involving gene editing technology that sought relief under the Safe Harbor Provision of the Hatch-Waxman Act. Specifically, the court found the patentee’s complaint sufficiently alleged at least some uses of the claimed technology that, when taken as true, were not solely uses of a “patented invention” that were “reasonably related” to an FDA submission.

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.